Login to Your Account



53rd Annual American Society of Hematology

Pharmacyclics' PCI-32765: Lymphocyte Counts Rise, Then Response Rates Do

By Anette Breindl
Science Editor

Tuesday, December 13, 2011
SAN DIEGO – Pharmacyclics Inc. grabbed the spotlight on Friday with a $150 million up-front deal that could reach a total of $975 million with Janssen Biotech Inc. for Phase II hematologic cancer drug PCI-32765. At the 53rd Annual American Society of Hematology meeting, hematologists and investors got to see some of what all the fuss is about.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription